NCT07412444Recruiting
EVOO and Metabolic Liver Health in MASLD
Evaluation of the Effects of Extra Virgin Olive Oil Consumption on Hepatic Steatosis Parameters and on Glucose and Lipid Metabolism in Subjects With MASLD.
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and other cardio-metabolic risk factors. Lifestyle modification, particularly through the Mediterranean Diet, is the first-line intervention, and extra virgin olive oil is a key component thanks to its monounsaturated fatty acids and bioactive compounds with anti-inflammatory and antioxidant effects. Several studies indicate that extra virgin olive oil supplementation, especially within a Mediterranean Diet pattern, reduces hepatic steatosis, improves inflammation, oxidative stress, and glucose and lipid profiles, and may promote weight loss and reduction of fat mass, also through potential effects on the gut microbiota. EFSA recognizes protective effects with a daily intake of at least 20 g of extra virgin olive oil, but it is still unclear whether this amount is optimal for individuals with MASLD, particularly those who are overweight or obese
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 16 Jan 2026
- Start date
- 6 May 2026
- Primary completion date
- 6 May 2027
- Lead sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07412444
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 6 May 2026 to the primary completion date, 6 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of any condition that may influence the occurrence of steatosis other than the conditions representing inclusion criteria.
- Severe medical conditions that may compromise participation in the trial.
Other
- Subjects with BMI \< 20 and BMI \> 30.
- Pregnancy or breastfeeding.
- Individuals following a special diet.
Who the study is looking for
- Subjects with 20 ≤ BMI \< 30;
- Age range between 18 and 65 years, both sexes;
- Diagnosis of hepatic steatosis, made on the basis of recognized criteria (FibroScan \[CAP (controlled attenuation parameter) \> 288 dB/m\], FLI).
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UOS Data Science Coordinator of this site? Confirm its status | Castellana Grotte | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.